U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H26N2O4S
Molecular Weight 378.486
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GEMOPATRILAT

SMILES

CC1(C)CCC[C@H](NC(=O)[C@@H](S)CC2=CC=CC=C2)C(=O)N1CC(O)=O

InChI

InChIKey=YRSVDSQRGBYVIY-GJZGRUSLSA-N
InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H26N2O4S
Molecular Weight 378.486
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 15:35:29 UTC 2023
Edited
by admin
on Fri Dec 15 15:35:29 UTC 2023
Record UNII
MU9089C77W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GEMOPATRILAT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
Gemopatrilat [WHO-DD]
Common Name English
GEMOPATRILAT [USAN]
Common Name English
1H-AZEPINE-1-ACETIC ACID, HEXAHYDRO-6-(((2S)-2-MERCAPTO-1-OXO-3-PHENYLPROPYL)AMINO)-2,2-DIMETHYL-7-OXO-, (6S)-
Common Name English
(6S)-Hexahydro-6-[(αS)-α-mercaptohydrocinnamamido]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid
Common Name English
gemopatrilat [INN]
Common Name English
BMS-189921
Code English
Classification Tree Code System Code
NCI_THESAURUS C247
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
NCI_THESAURUS C783
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C99557
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
SMS_ID
300000034217
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
ChEMBL
CHEMBL107747
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
FDA UNII
MU9089C77W
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
PUBCHEM
9886079
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
USAN
LL-99
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
CAS
160135-92-2
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
WIKIPEDIA
GEMOPATRILAT
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
INN
8055
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID901029484
Created by admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
EXCRETED UNCHANGED
No gemopatrilat was detected in urine and feces.
FECAL; URINE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
Term
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
MINOR
PLASMA
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
Metabolites M9 and M10, which were not well resolved, accounted for 8% of the radioactivity
PLASMA
METABOLITE -> PARENT
The prominent metabolites in the 1-h human plasma before DTT reduction were M2, M13, and M14, which together accounted for 31% of the radioactivity.
MAJOR
PLASMA
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MAJOR
FECAL
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
Metabolites M9 and M10, which were not well resolved, accounted for 8% of the radioactivity
PLASMA
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

Biological Half-life PHARMACOKINETIC P.O. ADMINISTRATION

Tmax PHARMACOKINETIC P.O. DMINISTRATION

ORAL BIOAVAILABILITY PHARMACOKINETIC
Tmax PHARMACOKINETIC INTRAVENOUS ADMINISTRATION